15 completed, 5 unknown, 2 active not recruiting, 1 not yet recruiting. 25 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 15, Unknown 5, Active not recruiting 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Enterobacteriaceae Infections: new trials by email Literature Review of Enterobacteriaceae Infections trials Research Report on Enterobacteriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine S. Flexneri-S. Sonnei bivalent conjugate vaccine, Placebo - Dysentery, Dysentery, Shigella | Phase 3 | Active not recruiting | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 8000 | 2025-05-12 | 2026-04-01 |
| ZyVac-TCV Bangladesh Study Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV - Typhoid Vaccination, Typhoid | Phase 3 | Not yet recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 4000 | 2025-04-01 | 2025-02-07 |
| Fecal Transplantation to Eradicate Colonizing Emergent Superbugs Fecal Microbiota Transplantation (FMT) capsules, Placebo capsules - Enterobacteriaceae Infections, Fecal Microbiota Transplantation | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 214 | 2024-01-11 | 2025-05-25 |
| Co-administration Study of OCV, TCV and MR Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) - Typhoid, Cholera | Phase 3 | Unknown | International Centre for Diarrhoeal Disease Research, Bangladesh | 2117 | 2023-10-14 | 2023-10-13 |
| Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, Placebo - Dysentery, Shigellosis | Phase 3 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 21000 | 2021-12-11 | 2022-01-11 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague Ciprofloxacin, Streptomycin, Gentamicin - Plague, Bubonic, Plague, Pneumonic | Phase 3 | Completed | University of Oxford | 222 | 2020-02-15 | 2025-03-06 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV® - Typhoid | Phase 3 | Unknown | International Vaccine Institute | 1800 | 2019-11-15 | 2020-04-22 |
| Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A) - Typhoid | Phase 3 | Active not recruiting | University of Maryland, Baltimore | 30000 | 2018-02-21 | 2026-09-17 |
| Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens Polymyxin B - Trauma, Resistant Infection | Phase 3 | Unknown | University of Puerto Rico | 40 | 2017-05-25 | 2019-02-08 |
| Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae Antipseudomonal beta-lactam antibiotic, De-escalation(short-spectrum antibiotic) - Enterobacteriaceae Infections | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 344 | 2016-10-01 | 2020-07-17 |
| Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Sitafloxacin, Ertapenem - Anti-Infective Agents, Urinary, Escherichia Coli Infections | Phase 2 / Phase 3 | Unknown | Khon Kaen University | 30 | 2016-07-01 | 2023-03-08 |
| Nepal Undifferentiated Febrile Illness Trial Azithromycin, Co-trimoxazole - Undifferentiated Febrile Illness | Phase 3 | Completed | Oxford University Clinical Research Unit, Vietnam | 330 | 2016-05-23 | 2023-12-06 |
| Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae 7 days course of antibiotic treatment, 14 days course of antibiotic treatment - Enterobacteriaceae Infections, Bloodstream Infection | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 238 | 2014-09-01 | 2017-03-13 |
| Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli Fosfomycin sodium intravenous, Meropenem intravenous, Ceftriaxone intravenous - Infection Due to ESBL Escherichia Coli | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 161 | 2014-07-01 | 2019-08-06 |
| Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Vi polysaccharide - Salmonella Infections, Typhoid Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 200 | 2012-05-01 | 2014-05-12 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S. Rifaximin - Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 660 | 2005-12-01 | 2019-11-25 |
| Rifaximin for Prevention of Travellers' Diarrhea Rifaximin, Placebo - Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 210 | 2005-06-01 | 2019-12-18 |
Showing 20 of 25. Sign in to see all of them.
Typhoid Fever (10) · Dysentery, Bacillary (5) · Escherichia coli Infections (5) · Bacteremia (3) · Dysentery (3) · Recurrence (3) · Sepsis (3) · Bacterial Infections (2) · Diarrhea (2) · Klebsiella Infections (2) · Plague (2) · Urinary Tract Infections (2) · Cholera (1) · Communicable Diseases (1)
Bacterial Infections and Mycoses (25) · Gram-Negative Bacterial Infections (25) · Infections (25) · Bacterial Infections (23) · Salmonella Infections (9) · Pathological Conditions, Signs and Symptoms (7) · Digestive System Diseases (6) · Disease Attributes (5) · Gastroenteritis (5) · Gastrointestinal Diseases (5) · Intestinal Diseases (5) · Pathologic Processes (5) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Ciprofloxacin (2) · Ertapenem (2) · Gentamicins (2) · Imipenem (2) · Rifaximin (2) · Streptomycin (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · Vi polysaccharide vaccine, typhoid (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Ampicillin (1) · Anti-Bacterial Agents (1) · Azithromycin (1) · Aztreonam (1) · Capsules (1) · Carrier Proteins (1)
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (3) · International Centre for Diarrhoeal Disease Research, Bangladesh (3) · Bausch Health Americas, Inc. (2) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · International Vaccine Institute (2) · Assistance Publique - Hôpitaux de Paris (1) · Centers for Disease Control and Prevention (1) · EuBiologics Co.,Ltd (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GlaxoSmithKline (1) · Khon Kaen University (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis (1) · Oxford University Clinical Research Unit, Vietnam (1) · Sanofi Pasteur, a Sanofi Company (1)
Spain (3) · Bangladesh (2) · Madagascar (2) · Nepal (2) · Philippines (2) · United States (2) · Canada (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Malawi (1) · Mexico (1)
Lin Du (2) · Buddha Basnyat, MBBS,MSc,MD (1) · Ganesh Kumar Rai, MD (1) · Howard Trachtman (1) · Jose Molina Gil-Bermejo, MD. PhD (1) · Josefina C Carlos, MD (1) · Juan M Maldonado Lozada, PharmD (1) · Kevin Griffith, MD, MPH (1) · Luis Eduardo Lopez Cortes, MD, PhD (1) · Martin Schriefer, PhD (1) · Matthew Laurens, MD (1) · Md Taufiqul Islam, MBBS, MPH (1)
PMID 12966125, PMID 15269195, PMID 17121631, PMID 17554249, PMID 18199038, PMID 18444865, PMID 18625681, PMID 19374579, PMID 20056180, PMID 20175247, PMID 20412178, PMID 21793988, PMID 22252816, PMID 22752516, PMID 23394211, PMID 23616495, PMID 23697744, PMID 24191943, PMID 24514083, PMID 24873986, PMID 25308927, PMID 25430979, PMID 25461655, PMID 25829373, PMID 26259799, PMID 27418577, PMID 28601833, PMID 28969659, PMID 30845320, PMID 32807214, PMID 32991678, PMID 34219224, PMID 34525285, PMID 34942090, PMID 35024838, PMID 35664443, PMID 35961356, PMID 36774331, PMID 3752106, PMID 38215770, PMID 38281499, PMID 38970065, PMID 40277027, PMID 40768716, PMID 9727997
2019 (1), R01DK052147 (1)